Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for 03KSI6WLXH

    Client Email Product

    03KSI6WLXH

    APIs // Active Pharmaceutical Ingredients

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    1
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    1
    API REF. PRICE (USD / KG)

    0

    API Market Place

    3
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    19.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    107
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    11
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Shionogi and Ferrer sign an agreement for the promotion in Spain of Rizmoic® (naldemedine), a treatment for opioid-induced constipation
    Shionogi and Ferrer sign an agreement for the promotion in Spain of Rizmoic® (naldemedine), a treatment for opioid-induced constipation

    https://www.ferrer.com/es/node/49

    PRESS RELEASE
    20 Jun 2019
    Share Share
    SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC®
    SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC®

    https://www.businesswire.com/news/home/20190521005648/en

    BUSINESSWIRE
    22 May 2019
    Share Share
    Determination of Regulatory Review Period for Purposes of Patent Extension
    Determination of Regulatory Review Period for Purposes of Patent Extension

    https://www.federalregister.gov/documents/2019/04/15/2019-07459/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symproic

    FEDERAL REGISTER
    15 Apr 2019
    Share Share
    Sandoz to commercialize Shionogi's Rizmoic in Germany, UK and Netherlands
    Sandoz to commercialize Shionogi's Rizmoic in Germany, UK and Netherlands

    http://www.pharmabiz.com/NewsDetails.aspx?aid=115178&sid=2

    PHARMABIZ
    11 Apr 2019
    Share Share
    Shionogi Concludes a Contract for the Commercialization of Rizmoic®
    Shionogi Concludes a Contract for the Commercialization of Rizmoic®

    https://www.businesswire.com/news/home/20190410005751/en

    BUSINESSWIRE
    11 Apr 2019
    Share Share
    Shionogi NV's Rizmoic (Naldemedine tosilate) Receives Approval in Europe
    Shionogi NV's Rizmoic (Naldemedine tosilate) Receives Approval in Europe

    https://www.ema.europa.eu/documents/overview/rizmoic-epar-medicine-overview_en.pdf

    EMA
    23 Mar 2019
    Share Share
    Two years following US approval, Japan’s Shionogi wins EU green light
    Two years following US approval, Japan’s Shionogi wins EU green light

    https://endpts.com/two-years-following-us-approval-japans-shionogi-wins-eu-green-light-for-opioid-constipation-drug/

    Natalie Grover ENDPTS
    22 Feb 2019
    Share Share
    Shionogi Regains Full Rights to Symproic® (naldemedine) in the US
    Shionogi Regains Full Rights to Symproic® (naldemedine) in the US

    http://www.shionogi.com/newsroom/article.html#122531

    PRESS RELEASE
    09 Jul 2018
    Share Share
    Fifty-Two Week Safety Study on Symproic® (naldemedine) for (OIC)
    Fifty-Two Week Safety Study on Symproic® (naldemedine) for (OIC)

    http://www.shionogi.com/newsroom/article.html#122526

    PRESS RELEASE
    23 Mar 2018
    Share Share
    Shionogi & Purdue Pharma Announce U.S. Availability of Symproic® (naldemedine)
    Shionogi & Purdue Pharma Announce U.S. Availability of Symproic® (naldemedine)

    http://www.shionogi.com/newsroom/article.html#122522

    12 Oct 2017
    Share Share
    FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II
    FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II

    http://www.shionogi.com/newsroom/article.html#122509

    23 Mar 2017
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search